By Timothy S. Donahue

Top Takeaways:

• Age-Gating Optional: FDA says device access restrictions are not mandatory for authorization of flavored vaping products.
• Vuse Questions: Glas sought clarification after Reynolds marketed flavored Vuse Pro pods for non-age-gated Alto devices.
• Policy Unchanged: Glas CEO Sean Greenbaum says FDA’s response is consistent with its previous communications.

The FDA says flavored vapes don’t necessarily need a digital bouncer at the door.

In a letter dated October 26 to Glas Inc., Bret Koplow, director of the Food and Drug Administration’s Center for Tobacco Products (CTP), clarified that device access restrictions (DAR), including age-verification technology, are not required for flavored electronic nicotine delivery systems (ENDS) to obtain marketing authorization.

The response followed a September 14 letter from Glas CEO Sean Greenbaum, who questioned the agency’s position after Reynolds American began marketing flavored Vuse Pro pods that Glas said were intended for use with Vuse Alto devices that lacked age-gating technology.

“FDA has not changed its posture with respect to device access restrictions,” Koplow wrote.

The agency continues to view age-gating as a potentially important tool for preventing youth use while still allowing adults access to lower-risk alternatives.

“Deployment of age-gating and other youth restriction technologies could therefore be one way potentially to facilitate the availability of an expanded range of adult-appealing ENDS flavors while confidently protecting children and preventing a new generation from becoming addicted to nicotine,” Koplow wrote. “However, device access restrictions are not the only way.”

Koplow explained that flavored products may receive authorization if manufacturers demonstrate that their benefits for adult smokers outweigh potential risks, including youth use.

“FDA does not require device access restrictions for flavored ENDS to be authorized; rather it is one approach within the broader case-by-case review framework for premarket tobacco product application (PMTA) review,” he wrote.

The clarification addresses a question raised by Glas after the FDA authorized its G2 vaping system in May 2026, including flavored products that incorporate age-verification technology.

In its September letter, Glas cited earlier FDA statements that emphasized the importance of device-access restrictions when evaluating flavored ENDS applications.

“This marketing approach appears incompatible with FDA’s previously articulated policy that flavored ENDS products require device access restrictions (DAR) to protect youth,” Greenbaum wrote, referring to Reynolds’ Vuse Pro pod strategy.

Glas identified Peach, Berry, Watermelon, and Fresh Mint Vuse Pro pods that it said were marketed for use with Vuse Alto devices. According to Glas, the Vuse Pro device incorporates mandatory age verification, whereas Alto does not.

The company also cited an August 20 FDA letter stating that, among the restrictions identified to date, only DAR had demonstrated the potential to significantly alter the agency’s assessment of flavored ENDS products.

“If the Agency’s position has changed, Glas must know in order to modify its business plans,” Greenbaum wrote.

Koplow’s response did not directly determine whether Reynolds’ marketing practices comply with FDA requirements. Instead, it distinguished between the standards for obtaining marketing authorization and the agency’s enforcement priorities regarding unauthorized products with pending applications.

The FDA said it generally does not intend to prioritize enforcement of the premarket authorization requirement for certain products with accepted and filed applications, subject to additional conditions for non-tobacco-flavored ENDS.

The agency emphasized that it may still prioritize products with youth-appealing features or those with safety concerns.

Koplow also addressed Glas’s plans for supplemental PMTAs and encouraged manufacturers to consult CTP’s Office of Science before submitting applications for modified versions of previously authorized products.

Asked whether Koplow’s response contradicted the FDA’s earlier communications on age-gating, Greenbaum told Nicotine Insider, “No, it’s consistent.”

He also said the clarification would not change Glas’s product development plans.

“Since receiving MGOs in March 2026 and May 2026, Glas has submitted additional product supplements to FDA which the agency has accepted,” Greenbaum said. “The Company’s focus is on its own products and it can’t speak to other companies in the space and their products.”

The exchange underscores the distinction between technologies that may strengthen a flavored product’s chances of authorization and the measures the FDA considers mandatory.